Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
A 13-deoxy anthracycline and a taxane can be administered to a patient simultaneously, separately, sequentially, or consecutively to produce a therapeutic anticancer effect with reduced toxicity and side effect profile, compared to the administration of equieffective amounts of either compound alone. A composition or preparation of a 13-deoxy anthracyclines and a taxane for producing a potent anticancer therapeutic effect is also provided.
1. A therapeutically effective amount of a synergistic anticancer combined preparation, in which the cancer is sensitive to a synergistic combination comprising a first compound and of a second compound, wherein:
the first compound is a 13-deoxyanthracycline, or pharmaceutically acceptable salts or prodrugs thereof, said 13-deoxyanthracycline having the formula:
wherein
each of R 1 , R 2 and R 3 is independently selected from the group consisting of H and OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is selected from the group consisting of O and NH; and
R 6 is a sugar moiety; and
the second compound is a taxane.
2. The preparation of claim 1 , wherein said 13-deoxyanthracycline is selected from the group consisting of 13-deoxydoxorubicin, 13-deoxydaunorubicin, 13-deoxycaminomycin, 13-deoxyepirubicin, 13-deoxyidarubicin, 13-deoxyannamycin, 13-deoxyamrubicin and the 5-imino analogs thereof, and said taxane is selected from the group consisting of paclitaxel and docetaxel.
3. A pharmaceutical composition comprising the preparation of claim 1 , and a pharmaceutically acceptable carrier or excipient.
4. A pharmaceutical composition comprising the preparation of claim 2 , and a pharmaceutically acceptable carrier or excipient.
5. The preparation of claim 1 , wherein said sugar moiety is selected from the group consisting of daunosamine, epidaunosamine, and a rhamnal sugar.
6. A method for treating cancer comprising administering to a mammal in need thereof a therapeutically effective amount of a synergistic combination comprising:
(a) a 13-deoxyanthracycline, or pharmaceutically acceptable salts or prodrugs thereof, said 13-deoxyanthracycline having the formula:
wherein
each of R 1 , R 2 and R 3 is independently selected from the group consisting of H and OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is selected from the group consisting of O and NH; and
R 6 is a sugar moiety; and
a taxane, wherein the 13-deoxyanthracycline and the taxane are administered simultaneously, separately, or sequentially to produce a synergistic anticancer effect, and wherein the cancer is sensitive to the synergistic combination.
7. The method of claim 6 , wherein said sugar moiety is selected from the group consisting of daunosamine, epidaunosamine, and a rhamnal sugar.
8. The method of claim 6 , wherein said 13-deoxyanthracycline is selected from the group consisting of 13-deoxydoxorubicin, 13-deoxydaunorubicin, 13-deoxycaminomycin, 13-deoxyepirubicin, 13-deoxyidarubicin, 13-deoxyannamycin, 13-deoxyamrubicin and the 5-imino analogs thereof, and said taxane is selected from the group consisting of paclitaxel and docetaxel.
9. A therapeutically effective amount of a synergistic anticancer combined preparation, in which the cancer is sensitive to a synergistic combination, comprising a first compound and of a second compound, wherein:
the first compound is a 5-imino-13-deoxy anthracycline, or pharmaceutically acceptable salts or prodrugs thereof, said 5-imino-13-deoxy anthracycline having the formula:
wherein
each R 1 , R 2 and R 3 is independently selected from the group consisting of H and OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is a sugar moiety; and
the second compound is a taxane.
10. The preparation of claim 9 , wherein said 5-imino-13-deoxy anthracycline is selected from the group consisting of 5-imino-13-deoxydoxorubicin, 5-imino-13-deoxydaunorubicin, 5-imino-13-deoxycaminomycin, 5-imino-13-deoxyepirubicin, 5-imino-13-deoxyidarubicin, 5-imino-13-deoxyannamycin, and 5-imino-13-deoxyamrubicin, and said taxane is selected from the group consisting of paclitaxel and docetaxel.
11. A pharmaceutical composition comprising the preparation of claim 9 , and a pharmaceutically acceptable carrier or excipient.
12. A pharmaceutical composition comprising the preparation of claim 10 , and a pharmaceutically acceptable carrier or excipient.
13. The preparation of claim 9 , wherein said sugar moiety is selected from the group consisting of daunosamine, epidaunosamine, and a rhamnal sugar.
14. A method for treating cancer which comprises administration to a mammal in need thereof a therapeutically effective amount of a synergistic combination comprising:
(a) a 5-imino-13-deoxyanthracycline, or pharmaceutically acceptable salts or prodrugs thereof, said 5-imino-13-deoxy anthracycline having the formula:
wherein
each R 1 , R 2 and R 3 is independently selected from the group consisting of H and OH;
R 4 is selected from the group consisting of H, OH, alkyl, and O-alkyl;
R 5 is a sugar moiety; and
(b) a taxane, wherein the 5-imino-13-deoxyanthracycline and the taxane are administered simultaneously, separately, or sequentially to produce a synergistic anticancer effect, and wherein the cancer is sensitive to the synergistic combination.
15. The method of claim 14 , wherein said sugar moiety is selected from the group consisting of daunosamine, epidaunosamine, and a rhamnal sugar.
16. The method of claim 14 , wherein said 5-imino-13-deoxy anthracycline is selected from the group consisting of 5-imino-13-deoxydoxorubicin, 5-imino-13-deoxydaunorubicin, 5-imino-13-deoxycaminomycin, 5-imino-13-deoxyepirubicin, 5-imino-13-deoxyidarubicin, 5-imino-13-deoxyannamycin, and 5-imino-13-deoxyamrubicin, and said taxane is selected from the group consisting of paclitaxel and docetaxel.
17. The preparation of claim 1 , wherein the preparation possesses an anti-cancer growth potency that is between 20 and 400 times higher than an anti-cancer growth potency of said taxane.
18. The preparation of claim 1 wherein said first compound is present in an amount that is lower than its therapeutically effective amount.
19. The preparation of claim 9 wherein said first compound is present in an amount that is lower than its therapeutically effective amount.
20. The method of claim 6 wherein said first compound is administered in an amount that is lower than its therapeutically effective amount.
21. The method of claim 14 wherein said first compound is administered in an amount that is lower than its therapeutically effective amount.